Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AXYS Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (274)	5/26/1999 9:30:00 PM
From: David Bogdanoff	Read Replies (1) \| Respond to of 455

BZ; Well, tryptase works on out of control mast cells which Axys' people feel are lead to asthma symptoms and possibly psoriasis symptoms also. I didn't hear them say that one application logically extends to another; I suppose it could work for one disease but not well enough in another. One problem with psoriasis is that there is no animal model for itand relatively little is known about it, compared to asthma. Thus, the research strategy is different, smaller and more exploratory for psoriasis. As far as asthma is concerned, the strategy is to replace steroid treatment with an oral tryptase product. This will involve phase IIb studies which are justified by a more advanced knowledge of asthma. David